Latanoprost is a prostaglandin analog indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. It is available as eye drops and ophthalmic solution for topical use. MedsAcross supplies Latanoprost for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Latanoprost ophthalmic solution is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Latanoprost ophthalmic solution is a prostaglandin F 2α analogue indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Source: US FDA prescribing information
Latanoprost is a prostaglandin F 2α analogue that is believed to reduce the IOP by increasing the outflow of aqueous humor. Studies in animals and man suggest that the main mechanism of action is increased uveoscleral outflow. Elevated IOP represents a major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss.
Source: US FDA prescribing information
The recommended dosage is one drop in the affected eye(s) once daily in the evening. If one dose is missed, treatment should continue with the next dose as normal. The dosage of latanoprost ophthalmic solution should not exceed once daily, the combined use of two or more prostaglandins, or prostaglandin analogs including latanoprost ophthalmic solution is not recommended. It has been shown that administration of these prostaglandin drug products more than once daily may decrease the IOP lowering effect or cause paradoxical elevations in IOP. Reduction of the IOP starts approximately 3 to 4 hours after administration and the maximum effect is reached after 8 to 12 hours. Latanoprost ophthalmic solution may be used concomitantly with other topical ophthalmic drug products to lower IOP.
Source: US FDA prescribing information
Known hypersensitivity to latanoprost, benzalkonium chloride, or any other ingredients in this product.
Source: US FDA prescribing information
• Pigmentation: Pigmentation of the iris, periorbital tissue (eyelid) and eyelashes can occur. Iris pigmentation likely to be permanent. • Eyelash Changes: Gradual change to eyelashes including increased length, thickness and number of lashes. Usually reversible.
Source: US FDA prescribing information
The following adverse reactions were reported in postmarketing experience and are discussed in greater detail in other sections of the label: • Iris pigmentation changes • Eyelid skin darkening • Eyelash changes (increased length, thickness, pigmentation, and number of lashes) • Intraocular inflammation (iritis/uveitis) • Macular edema, including cystoid macular edema Most common adverse reactions (5-15%) from clinical trials are blurred vision, burning and stinging, conjunctival hyperemia, foreign body sensation, itching, increased pigmentation of the iris, and punctate keratitis.
Source: US FDA prescribing information
Store unopened bottle(s) under refrigeration at 2°C to 8°C (36°F to 46°F). During shipment to the patient, the bottle may be maintained at temperatures up to 40°C (104°F) for a period not exceeding 8 days. Once a bottle is opened for use, it may be stored at room temperature up to 25°C (77°F) for 6 weeks. Protect from light.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
5 presentations of Latanoprost, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Latanoprost 50 mcg/mL eye dropsOphthalmic Cold chainGeneric name | — | US FDA | Available on request |
| Latanoprost 50 mcg/mL ophthalmic solutionOphthalmic Cold chainGeneric name | — | US FDA | Available on request |
| Xelpros 0.05 mg/mL eye dropsOphthalmic, topical | Sun Pharmaceutical IndustriesIndia | US FDA | Available on request |
| Iyuzeh 50 mcg/mL eye dropsOphthalmic | Thea Pharma | US FDA | Available on request |
| Xalatan 50 mcg/mL eye dropsOphthalmic Cold chain | Viatris Specialty | US FDA | Available on request |
3 brand names across 1 markets.
Indian manufacturers are highlighted.
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Latanoprost in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 5 presentations of Latanoprost and sources them for licensed hospitals, importers and physicians against valid import documents. Indian manufacturers include Sun Pharmaceutical Industries.
The catalogue lists 3 brand names for Latanoprost, including Iyuzeh, Xalatan, Xelpros.
Yes. The US FDA first approved Latanoprost on 5 June 1996, according to Drugs@FDA.
Yes. Latanoprost has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
At least one listed presentation of Latanoprost must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Latanoprost is classified under ATC code S01EE01 (Latanoprost).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.